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Abstract
Background: Highly active antiretroviral therapy for AIDS is known to increase cardiovascular risk, but the effects of 
potent antiretroviral agents according to gender are unknown. 
Objective: The present study evaluated the impact of HIV infection treatment on aortic stiffness according to gender.
Methods: From university-affiliated hospitals, we recruited 28 AIDS patients undergoing highly active antiretroviral 
treatment (HAART), 28 treatment-naïve HIV-infected patients, 44 patients with type 2 diabetes, and 30 controls. Aortic 
stiffness was determined by measuring pulse wave velocity (PWV) using a validated and non-invasive automatic device. 
Results: The crude mean PWV values and 95% confidence intervals (95% CI) for HAART, diabetics, and controls were 
9.77 m/s (95% CI 9.17-10.36), , 9.00 m/s (95% CI 8.37-9.63), 9.90 m/s (95% CI 9.32-10.49),  and 9.28 m/s (95% CI 8.61-
9.95), respectively, for men (P-value for trend = 0.14), and 9.61 m/s (95% CI 8.56-10.66), 8.45 m/s (95% CI 7.51-9.39), 
9.83 (95% CI 9.21-10.44), and 7.79 m/s (95% CI 6.99-8.58), respectively, for women (P-value for trend <0.001). Post-hoc 
analysis revealed a significant difference between the mean PWV values in the HAART group and controls in women 
(P-value <0.01). After adjusting for other potential covariates, including systolic blood pressure and diabetes, these 
results did not change. The findings indicate that the impact of HAART treatment on aortic stiffness was amplified in 
women with hypertension, dyslipidemia, and metabolic syndrome.  
Conclusion: Potent anti-retroviral agents used in the treatment of HIV infection increases aortic stiffness, mainly among 
women with higher cardiovascular risk. (Arq Bras Cardiol 2012;99(6):1100-1107)
Keywords: Anti Retroviral Agents; Acquired Immunosyndrome / therapy; HIV Infections / complications; Vascular 
Stiffness / drug effects.
augmentation showing a positive association15-22. No differences 
were found in PWV in a cohort of women in Rwanda when 
comparing HIV-infected women undergoing HAART and others 
not using HAART23.
All studies described above are heterogeneous considering the 
population studied, time since infection, duration of treatment, 
and device used to measure PWV. Only six studies analyzed 
women16,17, 21-23,  totaling 39 females, as the cohort of women 
in Rwanda did not have a long HAART exposure to permit 
comparisons23. The search for gender differences is justified by 
a large registry of myocardial infarction in the United States that 
found a risk of 40% for HIV-positive men compared to HIV-free 
men, in contrast to a three-fold risk for HIV-infected women 
compared to HIV-free females24. 
In Brazil, AIDS mortality has decreased significantly since 1997 
when HAART became available at the public health system free 
of costs. During the past decade, the profile of infected Brazilians 
has shifted from urban middle/upper class men to poor women25. 
We recruited a sample of HIV-infected subjects undergoing 
HAART without opportunistic infections and previous 
cardiovascular disease to verify the impact of HIV treatment 
on aortic stiffness according to gender. We compared these 
Introduction 
Highly active antiretroviral treatment (HAART) of HIV infection 
dramatically changed patient survival1. However, the treatment 
may be associated with a higher incidence of myocardial 
infarction mediated by an adverse cardiovascular risk factor 
profile2-9 and other conditions, such as high arterial stiffness, 
which could be affected by HIV infection or its treatment10, 11. 
Age, diabetes, hypertension, and kidney failure have been 
independently associated with increased aortic stiffness measured 
by pulse wave velocity (PWV) 12; and subjects with higher values 
have double the risk of a cardiovascular event, death, and all-
cause mortality13, 14.  
Some studies have addressed the effect of HIV infection 
or its treatment with HAART on arterial stiffness and aortic 
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subjects with type 2 diabetes patients as they also present a 
higher cardiovascular risk. 
Methods 
The AGATA (from the Portuguese, “Avaliação Geral da 
ATerosclerose em Adultos” General Evaluation of Atherosclerosis 
in Adults) is a cross-sectional study designed to evaluate the impact 
of HIV infection and its treatment on the cardiovascular system. 
Subjects
At the outpatient clinic of a university-affiliated hospital in 
São Paulo, Brazil, we identified 56 consecutive patients with 
HIV infection, 28 using HAART and 28 patients with a recent 
diagnosis of HIV infection but not using HAART. Causes of 
infection were heterosexual contact (40.3%), homosexual contact 
(45.6%), injection drug use (12.3%), and unknown (1.8%). None 
of the patients had current or recent opportunistic infections or 
hepatitis B or C. Forty-four patients with type 2 diabetes were 
recruited consecutively from the outpatient clinic of our hospital. 
Thirty controls were invited from a worksite for periodic health 
examinations in the same hospital and matched for age (10-year) 
and sex with both HIV groups. 
Enrollment Criteria
Inclusion criteria were age ranging from 20 to 69 years, at 
least 12 months of follow-up, and good compliance with HAART 
and type 2 diabetes treatment. Exclusion criteria were coronary 
heart disease (history of myocardial infarction, unstable angina, 
coronary revascularization), an electrocardiogram suggestive of 
past myocardial infarction, past history of cerebrovascular disease, 
peripheral artery disease, type 1 diabetes, creatinine clearance 
under 40 ml/min/1.73 m2, and use of prescribed statins or fibrates.
Parameter Evaluation
All participants were examined in the morning after a 12-hour 
fasting. Weight, height, and waist circumference were measured 
using standard techniques. Resting blood pressure was measured 
using an oscillometric sphygmomanometer (Omron 705CP) 
with standard techniques.  All participants, except those who 
reported a diagnosis of type 2 diabetes, were submitted to a 
glucose tolerance test.
Pulse Wave Velocity (PWV)
PWV was measured using a Complior-SP (Artech Medical, 
France). The transducers were placed over the suprasternal 
notch and femoral arteries. PWV was calculated by dividing the 
suprasternal notch -femoral distance by the difference in the 
transit time of the pulse waves digitally recorded in the carotid 
and right femoral artery (sampling rate 500 Hz). The PWV 
measurements were read by two researchers (RSC/JGM) blinded 
to the status of the participant.
Risk Factors
A participant was classified as hypertensive based on self-
reported medical diagnosis, current treatment, office systolic 
blood pressure ≥ 140 mmHg, or diastolic  ≥ 90 mmHg13; 
as diabetic based on self-reported medical diagnosis, current 
treatment, or a positive glucose tolerance test (glucose levels 
> 200 mg/dl after two hours); as dyslipidemic based on self-
reported medical diagnosis or a LDL-cholesterol ≥ 130 mg/dl. 
We did not apply specific blood pressure cut-offs for diabetics, 
and metabolic syndrome was defined according to standard 
criteria26. Glomerular filtration rate was calculated from serum 
creatinine applying the CKD-Epi  formula27
Statistical Analysis
Data are expressed as mean and 95% confidence interval 
(95% CI). Statistical analyses were performed using SPSS 16.0. 
Chi-square was used to compare categorical variables. The 
Spearman correlation coefficient was used to examine the 
association between PWV and other variables. Continuous 
variables were expressed as mean and standard error of the 
mean (SEM) and compared using Generalized Linear Models 
with a post hoc test of least square differences for multiple 
comparisons. PWV values were shown after adjusting for age 
using a generalized linear model. 
All analyses were adjusted firstly for age and sex, and 
secondly for systolic blood pressure. The full multivariate model 
was adjusted for age, sex, systolic blood pressure, glucose 
tolerance, waist circumference, glomerular filtration rate, and 
triglycerides (log) for all participants, and differently for men and 
women according to the univariate analysis. Because PWV was 
highly right-skewed, generalized linear models using maximum 
likelihood optimization were constructed to assess the association 
between risk factors and PWV. We present the exponential beta-
parameter estimates of PWV values calculated by the Wald test 
with 95% CI.
Ethical Issues
This study was approved by the Institutional Review Boards 
of the two hospitals, and all participants provided written 
informed consent.
Results 
The mean time since diagnosis of HIV infection was greater 
for HAART patients than treatment-naïve HIV patients (10.4±3.7 
vs. 6.5±4.8 years, p<0.001). The mean and standard deviation 
(SD) time of exposure to HAART was 7.7 (3.4) years. The mean 
(SD) nadir of CD4+ T-lymphocyte count was 207 (190) cells/
mm3 for the HAART group and 448(176) cells/mm3 for the 
treatment-naïve HIV-group; the current CD4+ cell count was 
701(400) cells/mm3 for the HAART group and 609(307) cells/mm3 
for treatment-naïve HIV patients. The median (SD) highest viral 
load during the course of infection was 3,741 (10,312) copies/
ml for the HAART group and 16,430 (27,151) copies/ml for the 
treatment-naïve group. Most of the HAART subjects had a well-
controlled viral load (<50 copies/mL) compared to none in the 
treatment-naïve HIV group (p<0.0001). No difference was found 
between the groups regarding C-reactive protein values. Four 
patients in the HAART group and one patient in the treatment-
naïve group were identified as type 2 diabetics.
The general characteristics of the subjects are shown in 
Table 1. Diabetic patients were older compared to HIV-
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Table 1 - General Characteristics and Cardiovascular Risk Factors According to Group and Gender
 HIV HAART HIV treatment-naive Type 2 Diabetes Controls
p-value from 
Analysis of Variance
MEN
N = 20 N =18 N = 21 N = 16
Age* (years) 45.0 ± 2.0‡ 41.7 ± 1.7‡ 46.2±1.1 41.6 ± 1.8‡ 0.13
Race (%) 0.23
White 12 (60) 10 (56) 10 (48) 6 (38)
Mixed 6 (30) 6 (33) 9 (42) 9 (56)
Black 2 (10) 2 (11) 2 (10) 1 (6)
Former/current smokers (%) 13 (65) 9 (50) 15 (71.4) 9 (56.3) 0.06
Body mass index* (kg/m2) 25.2 ± 0.6 §.|| 25.3 ± 0.8§ 30.1±1.0 31.6 ± 3.4 < 0.05
Waist circumference * (cm) 91.1 ± 2.1‡ 87.3 ± 2.2‡. ¶ 101.7±2.1 96.1 ± 2.8 < 0.001
Systolic blood pressure * (mm Hg) 127.4 ± 3.3# 117.4 ± 3.6‡ 131.9±10.9¶ 123.4 ± 7.4 < 0.01
High blood pressure† (%) 9 (45) 4 (22.2) 15 (71.4) 5 (31.3)
Fasting blood glucose* (mg/dl) 113.8 ± 4.2‡ 97.1 ± 2.6‡ 154.9 ±7.6 101.8   ± 2.0‡ < 0.001
Glycated hemoglobin* (g %) 5.2 ± 0.2 5.6 ± 0.1 7.5±0.4 6.0 ± 0.1 < 0.001
Metabolic syndrome † (%) 6 3 N/A 6
LDL-cholesterol* (mg/dl) 116.9 ± 5.3 110.4 ± 7.8 112.4±11.0 109.5 ± 7.6 0.153
Dyslipidemia † (%) 19 (95.0) 17 (94.4) 15 (75.0) 13 (81.3)
eGFR* (ml/min/1.73 m2) 82.1 ± 3.5 ± 87.6 ± 4.0 80.3± 3.3 76.9 ±  3.4 0.24
WOMEN
N = 8 N = 10 N = 23 N = 14
Age* (years) 41.9 ± 2.1‡ 42.6 ± 2.0‡ 51.8 ± 1.1 43.3 ± 2.3‡ < 0.001
Race (%) 0.23
White 1 (12.5) 4 (40.0) 13 (56.6) 7 (50.0)
Mixed 4 (50) 6 (60.0) 5 (21.7) 5 (35.7)
Black 3 (37.5) 0 (0) 5 (21.7) 2 (14.3)
Former/current smokers (%) 5(62.5) 5(50.0) 11(47.8) 6(42.9) 0.15
Body mass index* ( kg/m2) 25.5 ± 3.7§ 28.0 ± 6.8 31.1 ± 5.1 26.6 ± 5.2§ < 0.05
Waist circumference * (cm) 85.5 ± 3.6§ 86.2 ± 4.8§ 97.6 ± 2.3|| 81.3 ± 3.4 < 0.001
Systolic blood pressure* (mm Hg) 119.4 ± 2.5 119. 5±4.2 124.2 ± 2.6 115.4 ± 5.7 0.38
High blood pressure† (%) 3 (37.5) 4 (40.0) 21 (91.3) 3 (21.4)
Fasting blood glucose* (mg/dl) 98.5 ± 2.4‡ 99.7 ± 2.6‡ 139.5 ± 8.1 97,6 ± 1.9‡ < 0.001
Glycated hemoglobin* (g%) 5.0 ± 0.2 5.65 ± 0.2 6.8 ± 0.2 5.9  ±  0.1 < 0.001
Metabolic syndrome † (%) 2 3 3 ---
LDL-cholesterol* (mg/dl) 125.4 ± 36.3 120 ± 28.2 118.4 ± 32.7 129.0 ± 26.6 0.77
Dyslipidemia † (%) 7 (87.5) 5 (50.0) 21 (91.3) 6 (42.9)
eGFR* (ml/min/1.73 m2) 93.7 ± 5.6§ 97.9 ± 6.0‡ 76.4 ± 2.9 108.4 ± 6.3‡ < 0.001
HAART means highly active antiretroviral treatment for AIDS.
* Mean ± standard error of the mean. 
† The following definitions were adopted: (1) High blood pressure defined by self-reported medical history of hypertension, current treatment for hypertension, systolic 
blood pressure ≥ 140 mmHg, or diastolic blood pressure ≥ 90 mmHg; (2) Dyslipidemia defined as LDL-cholesterol ≥ 130 mg/dl or current treatment for dyslipidemia; 
(3) Metabolic syndrome was defined according to the 3rd Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment 
of High Blood Cholesterol in Adults. 24 ; (4) Glomerular filtration rate (eGFR) was calculated by the CKD-EPI  formula. 25
‡ p <0.01 versus type 2 diabetes; § p <0.05 versus type 2 diabetes ; || p <0.01 versus controls ;¶ p <0.05 versus controls
# p <0.05 versus treatment-naïve.
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infected patients and controls. Men with diabetes and 
controls had higher BMI and greater waist circumference 
compared to HIV-infected patients; only women with 
diabetes had a higher mean body mass index than the 
HAART group. High blood pressure was more common 
among diabetics in both sexes, but the mean systolic blood 
pressure was higher only among men with diabetes. Kidney 
function was impaired only in diabetic women.
Table 2 shows Spearman’s correlation coefficients for 
variables associated with PWV. The variables associated 
with PWV for both sexes were age, systolic blood pressure, 
waist circumference, and fasting blood glucose. For 
women, a correlation was identified between PWV and 
glycated hemoglobin and the glomerular filtration rate. 
An upward trend of the crude means for PWV is shown 
in Figure 1. Table 3 shows the crude values of PWV for 
all participants according to gender; the odds ratio for 
each category was calculated using the control group as 
the reference. 
Adding other variables associated with PWV (Table 2) 
did not change the previous age-adjusted means for 
PWV. An important difference was observed between 
sexes in the pattern of mean PWV according to category. 
Among men, no differences were detectable between the 
groups. In contrast, among women, a significant upward 
trend was observed with higher values for women with 
diabetes and those undergoing HAART. Post-hoc analysis 
revealed a significant difference in the mean PWV between 
Table 2 – Spearman Rank Correlation Coefficient for Pulse Wave Velocity
Age Body mass index
Waist 
circumference
Systolic
blood 
pressure
LDL 
Fasting
blood 
glucose
Glycated 
hemoglobin Leukocytes
C-reactive 
protein
Glomerular
filtration 
rate
Men 0.610† 0.216 0.375† 0.451† 0.05 0.301† 0.126 0.306† 0.227 -0.165
Women 0.546† 0.127 0.283* 0.516† 0.02 0.485† 0.337* 0.019 0.139 -0.409†
* p < 0.05; † p < 0.01
Figure 1 – Mean pulse wave velocity of HIV-infected patients undergoing Highly active antiretroviral treatment (HAART), HIV treatment-naïve patients, and controls. The 
error bars indicate 95% confidence interval
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participants receiving HAART and controls. The results 
were similar when we excluded all participants with 
diabetes from the analysis.
Finally, we analyzed the effect modification of other 
risk factors associated with aortic stiffness (Table 4). The 
impact of HAART on PWV was more pronounced among 
Caucasians compared to Non-Caucasians, and among 
nonsmokers compared to ex- and current smokers. The 
presence of hypertension significantly increased the 
mean values of PWV for patients undergoing HAART and 
diabetics compared to subjects without hypertension. A 
glomerular filtration rate < 80 ml/min blurred the effect 
of HAART on PWV. Metabolic syndrome altered the 
association of the HAART group compared to controls and 
the treatment-naïve group.
Discussion 
The results indicated increased PWV in HIV-infected 
patients undergoing HAART, mainly among women. HIV 
treatment-naïve patients did not have significantly higher 
PWV compared to controls. These results suggest that 
HAART, and not the HIV infection, is associated with 
increased arterial stiffness. The mean PWV values in HIV-
infected patients undergoing HAART were similar to the 
values obtained for diabetics of both sexes. The presence 
of hypertension, dyslipidemia, or metabolic syndrome 
amplified the association between HAART and PWV.
Arterial stiffness has been recognized as a relevant 
predictor of hypertension and cardiovascular events. PWV 
is measured using a non-invasive, reproducible technique 
available in epidemiological studies11-15. Higher PWV values 
Table 3 – Mean Pulse Wave Velocity (95% Confidence Interval) and the exponential of the β parameter obtained from the generalized linear 
models according to groups and gender
Controls HIV Treatment-naive Type 2 Diabetes HIV HAART p for trend
All participants
(n = 30) (n = 28) (n = 44) (n = 28)
Crude PWV (m/s) 8.58 (8.05 - 9.11) 8.80 (8.26 - 9.35) 9.86 (9.43 - 10.30) **,|| 9.72 (9.17 - 10.27) ||,#
Exp β parameter (age-adjusted) 1.00 (reference) 1.25 (0.58 - 2.67) 3.60 (1.81 - 7.14) 3.12 (1.46 - 6.68) < 0.001
Exp β parameter (multi-adjusted) 1.00 (reference) 1.25 (0.58 - 2.67) 3.60 (1.81 - 7.14) 3.12 (1.46 - 6.68) < 0.001
Men
(n = 16) (n = 18) (n = 21) (n = 20)
Crude PWV(m/s) 9.28 (8.61 - 9.95) 9.00 (8.37 - 9.63§ 9.90 (9.32 - 10.49) 9.77 (9.17 - 10.36)
Exp β parameter (age-adjusted) 1.00 (reference) 0.76 (0.30 - 1.89) 1.87 (0.77 - 4.52) 1.62 (0.66 - 3.97) 0.142
Exp β parameter (multi-adjusted) 1.00 (reference) 0.76 (0.30 - 1.89) 1.87 (0.77 - 4.52) 1.62 (0.66 - 3.97) 0.142
Women
(n = 14) (n = 10) (n = 23) (n = 8)
Crude PWV(m/s) 7.79 (6.99 - 8.58) 8.45 (7.51 - 9.39) 9.83 (9.21 - 10.44) ||,# 9.61 (8.56 - 10.66) ||
Exp β parameter (age-adjusted) 1.00 (reference) 1.94 (0.57 - 6.64) 7.69 (2.81 - 21.03) 6.21 (1.67 - 23.14) < 0.001
Exp β parameter (multi-adjusted) 1.00 (reference) 1.94 (0.57 - 6.79) 7.69 (2.76 - 22.19) 6.21 (1.62 - 23.10) < 0.001
All participants without type 2 diabetes
(n = 30) (n = 27) (n = 23)
Exp β parameter (age-adjusted) 1.00 (reference) 1.10 (0.52 - 2.35) N/A 2.56 (1.16 - 5.61) ||, # < 0.05
Men without type 2 diabetes
(n = 16) (n = 17) (n = 15)
Exp β parameter ( age and sex-adjusted) 1.00 (reference) 0.63 (0.26 - 1.56) - 1.21 (0.48 - 3.07) 0.35
Women without type 2 diabetes
(n = 14) (n = 10) (n = 8)
Exp β parameter (age-adjusted) 1.00 (reference) 1.94 (0.60 - 6.27) N/A 6.21 (1.77 - 21.79) || < 0.02
HAART means highly active antiretroviral treatment for AIDS; The full multivariate model was adjusted for age, sex, systolic blood pressure, glucose tolerance, 
waist circumference, glomerular filtration rate, and triglycerides (log); ‡ p <0.01 versus type 2 diabetes; § p <0.05 versus type 2 diabetes; || p <0.01 versus 
controls; ¶ p <0.05 versus controls
1104
Original Article
Eira et al.
AIDS Treatment and Arterial Stiffness
Arq Bras Cardiol 2012;99(6):1100-1107
suggest augmented arterial stiffness indicative of impaired 
elasticity of the artery wall that can be linked to future 
cardiovascular events14-16. Our results showing higher PWV 
values in patients undergoing HAART confirm previous 
data; however, this is the first study to show a significant 
impact among women. 
Few studies have evaluated large groups of treatment-
naïve HIV patients. Our results suggest that the treatment 
of HIV-infected patients with HAART has a greater impact 
on PWV than HIV infection itself. These data highlight the 
effect of HAART on the pathogenesis of arterial stiffness, in 
contrast with previously published results5, 19, 22.  Wijk et al.5 
evaluated PWV in 37 HIV-infected patients, 14 diabetics, 
and 13 controls, finding increased PWV only among 
type 2 diabetics. 5 The study also showed a correlation 
between the duration of HAART and increased PWV and 
inflammatory parameters. The authors concluded that both 
HIV infection and HAART are involved in the progression 
of arterial stiffness and atherosclerotic changes. Regarding 
the correlation of PWV with the duration of HAART, we 
showed similar results.5 
However, in our study, the HIV-infected patients had 
been using HAART for a mean of 8 years compared to 4.5 
years in the other study. Possibly, the longer duration of 
HAART in our study better demonstrated the impact on 
PWV. One difference is that we did not find any association 
between PWV and C-reactive protein, even with a similar 
proportion of participants with viral load < 50 copies/ml. 
Schillaci et al. showed increased aortic stiffness in HIV-
infected subjects in the absence of antiretroviral therapy22. 
In our study, subjects were older, with a higher BMI and 
included more women than the Peruggia study, and HIV-
infected treatment-naïve patients had PWV values very 
similar to controls. The assessment of arterial stiffness using 
applanation tonometry among HIV-infected Rwandan 
women (with or without HAART) did not show any 
differences in arterial wave reflection among the groups23. 
However, the duration of treatment was shorter and the 
women apparently had fewer cardiovascular risk factors 
than the women in our cohort. Analyzing the variables 
associated with increased PWV, age and systolic blood 
pressure were factors present in all groups. In previous 
studies, the duration of HAART was associated with greater 
PWV, but this was not confirmed in our analysis. 
The most relevant finding in the present study was that 
PWV values in the presence of HIV infection and HAART 
treatment were different according to gender. We analyzed 
24 women, whereas all previously published studies 
Table 4 – Effect of Modification on Mean Pulse Wave Velocity and 95% Confidence Interval Adjusted for Age and Sex According to Conditions 
Associated with Aortic Stiffness. Comparisons are shown by the age and sex-adjusted exponential β parameter of the generalized equation 
with 95% Confidence Interval
Controls HIV Treatment-naive Type 2 Diabetes HIV HAART p for trend
Race White(n = 40)
(n = 13)
1,00 (reference) 
(n = 14)
1.14 (0.43 - 3.06) §
(n = 23)
2.82 (1.16 - 6.86) ||
(n =13)
4.28 (1.57 - 11.67) ||.** < 0.01
Non-White
(n = 46)
(n = 17)
1,00 (reference)
(n = 14)
1.38 (0.45 - 4.25) ||. §
(n = 21)
4.79 (1.73 - 13.25)
(n = 15)
2.39 (0.79 - 7.22) < 0.05
Smoking habit Never(n = 47)
(n = 15)
1,00 (reference)
(n = 14) 
0.85 (0.26 - 2.72) ‡
(n = 18)
3.86 (1.29 - 11.5) ¶
(n = 18)
4.53 (1.26 - 16.3) ¶.# < 0.01
Former/current
(n = 39)
(n = 15)
1,00 (reference)
(n = 14)
1.83 (0.69 - 4.85)
(n = 26)
3.34 (1.43 - 7.81) ||
(n = 10)
2.45 (0.98 - 6.11) < 0.05
Hypertension No(n = 58)
(n = 22)
1,00 (reference)
(n = 20)
0.89 (0.41 - 1.95)
(n = 8)
1.95 (0.69 - 5.53)
(n = 16)
1.95 (0.85 - 4.47) 0.046
Yes
(n = 28)
(n = 8)
1,00 (reference)
(n = 8)
2.82 (0.63 - 12.61)
(n = 36)
3.62 (1.12 - 11.66) ¶
(n = 12)
5.43 (1.38 - 21.29) ¶ 0.001
Egfr  (<80 ml/min) No(n = 57)
(n = 19)
1,00 (reference)
(n = 19)
1.53 (0.64 - 3.67)
(n = 21)
3.63 (1.55 - 8.50) ||
(n = 19)
3.46 (1.45 - 8.30) || 0.001
Yes
(n = 27)
(n = 10)
1,00 (reference)
(n = 8)
0.75 (0.17 - 3.31)
(n = 21)
2.72 (0.82 - 9.09)
(n = 9)
2.62 (0.62 - 11.10) 0.023
Metabolic  syndrome No(n = 57)
(n = 21)
1,00 (reference)
(n = 21)
1.25 (0.52 - 2.98)
N/A (n = 15)
2.01 (0.78 - 5.23) 0.35
Yes
(n = 20)
(n = 6)
1,00 (reference)
(n = 6)
0.95 (0.26 - 3.47)
N/A (n = 8)
3.62 (1.09 - 12.00) ¶. # 0.06
Dyslipidemia No(n =  37)
(n = 11)
1,00 (reference)
(n = 6)
1.15 (0.37 - 3.58)
(n = 7)
3.41 (1.15 - 10.08) ¶
(n = 2)
1.11 (0.20 - 6.23) 0.14
Yes
(n = 39)
(n = 19)
1,00 (reference)
(n = 22)
1.15 (0.45 - 2.94) ‡
(n = 36)
3.22 (1.38 - 7.53) ¶
(n = 26)
2.85 (1.15 - 7.05) ¶ # < 0.01
HAART means highly active antiretroviral treatment for AIDS; ‡ p <0.01 versus type 2 diabetes; § p <0.05 versus type 2 diabetes; || p <0.01 versus controls; 
¶p <0.05 versus controls
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analyzed only 39 females16-17, 21, 22, as the cohort of women 
in Rwanda did not have a long HAART exposure to permit 
comparisons20. Importantly, although the number of women 
was lower compared to the number of men, we were able 
to show differences regarding the effect of HAART on aortic 
stiffness. We did not find other factors that could explain 
the sex differences. 
Hormonal changes could be investigated using animal 
studies. A study in LDL-null mice examined the effects 
of ritonavir and amprenavir on cholesterol accumulation 
in macrophages, showing that females had lowers levels 
than males. The protective effect was lost after genetically 
removing estrogen receptor-alpha28. 
The significant difference in mean PWV among 
participants with metabolic syndrome in our sample was 
different from previous results5. Although we were able to 
classify subjects according to glucose tolerance as normal or 
impaired, we did not detect a higher PWV among HAART 
patients with impaired glucose tolerance. We also observed 
the impact of dyslipidemia as increased PWV in the HAART 
group. These data disagree with a small clinical trial that 
did not report any aortic stiffness alterations in subjects 
using pravastatin compared to placebo29.  
This analysis has several strengths. Most studies included 
only men, whereas we have an adequate proportion of 
women in all groups. The diagnosis of diabetes was based 
on an oral glucose tolerance test, a gold standard for type 2 
diabetes diagnosis in epidemiological studies. The number 
of treatment-naïve HIV patients was higher compared to 
previous studies. The limitations are due to the cross-
sectional design and proportion of males in the control 
group with body mass index > 25 kg/m2. 
Although these results were different compared to the 
general population, they are representative of men in this 
worksite facility, and the skewed mean body mass index 
observed in the control group did not blur the comparison 
of PWV between HAART and control groups. 
Concluding, our results suggest that increased arterial 
stiffness in HIV-infected patients is associated more with 
the use of HAART than HIV infection itself, especially 
among women. 
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